{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:12:27Z","timestamp":1759385547808},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jns.2024.123176","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T21:33:34Z","timestamp":1723498414000},"page":"123176","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic factors associated with disability in a cohort of neuromyelitis optica spectrum disorder and MOG-associated disease from a nationwide Portuguese registry"],"prefix":"10.1016","volume":"464","author":[{"given":"Jo\u00e3o","family":"Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Sam\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f3nia","family":"Figueiroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cla\u00fadia","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sofia","family":"Correia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas Br\u00e1s","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Perdig\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e2nia","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Felgueiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hip\u00f3lito","family":"Nzwalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e2nia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Boleixa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmeralda","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Martins","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernestina","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123176_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123176_bb0015","doi-asserted-by":"crossref","first-page":"E2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123176_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2024.123176_bb0025","first-page":"7","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","author":"Redenbaugh","year":"2021","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.jns.2024.123176_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort","volume":"122","author":"Dauby","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2024.123176_bb0035","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123176_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic\u2019s Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0050","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123176_bb0055","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123176_bb0060","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123176_bb0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.msard.2018.12.010","article-title":"Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment","volume":"28","author":"Banerjee","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0070","doi-asserted-by":"crossref","first-page":"e1912732","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs Aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jns.2024.123176_bb0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/aian.aian_406_21","article-title":"A comparative analysis of clinical and imaging features of aquaporin 4 (AQP4) antibody positive, myelin oligodendrocyte glycoprotein (MOG) antibody positive and double seronegative subtypes of neuro myelitis Optica Spectrum disorder (NMOSD)","volume":"25","author":"Gupta","year":"2022","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0095","first-page":"56","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","author":"Santos","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0100","first-page":"59","article-title":"Pediatric neuromyelitis optica spectrum disorders in Portugal: a multicentre retrospective study","author":"Martins","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0105","first-page":"63","article-title":"Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups","author":"Santos","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.123176_bb0115","first-page":"48","article-title":"Anti-MOG associated disorder\u2013clinical and radiological characteristics compared to AQP4-IgG+ NMOSD\u2013A single-center experience","author":"Rempe","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0120","first-page":"361","article-title":"Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): a prospective observational study and review of literature","author":"RBR","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123176_bb0125","first-page":"347","article-title":"Predictores de discapacidad en una cohorte con espectro de neuromielitis \u00f3ptica","volume":"74","author":"Mu\u00f1oz","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0130","first-page":"13","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123176_bb0135","first-page":"13","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123176_bb0140","first-page":"13","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123176_bb0145","first-page":"6","article-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","author":"Sepulveda","year":"2019","journal-title":"Neurol. Neuroimmunol. neuroinflam."},{"key":"10.1016\/j.jns.2024.123176_bb0150","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123176_bb0155","first-page":"3","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol. Neuroimmunol. NeuroInflam."},{"key":"10.1016\/j.jns.2024.123176_bb0160","first-page":"36","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0165","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0170","first-page":"44","article-title":"Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina","author":"Rojas","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123176_bb0175","first-page":"8","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: part 1","author":"Graf","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.jns.2024.123176_bb0180","first-page":"8","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: part 2","author":"Graf","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.jns.2024.123176_bb0185","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","article-title":"Monoclonal antibody therapies beyond complement for NMOSD and MOGAD","volume":"19","author":"Redenbaugh","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2024.123176_bb0190","first-page":"364","article-title":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis","author":"Nepal","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.123176_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2022.2145879","article-title":"Transitioning immunotherapy in neuromyelitis optica spectrum disorder \u2013 when and how to switch","volume":"22","author":"Vishnevetsky","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jns.2024.123176_bb0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123176_bb0205","first-page":"48","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review","author":"Elsbernd","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123176_bb0210","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","article-title":"Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder","volume":"268","author":"Holm\u00f8y","year":"2021","journal-title":"J. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24003113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24003113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T21:21:08Z","timestamp":1724534468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24003113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"alternative-id":["S0022510X24003113"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123176","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors associated with disability in a cohort of neuromyelitis optica spectrum disorder and MOG-associated disease from a nationwide Portuguese registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123176"}}